Quantcast

Latest glioblastoma multiforme Stories

2014-02-25 08:30:35

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during...

2014-02-18 08:32:26

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Novocure announced today that Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center has licensed the NovoTAL (Transducer Array Layout) System. The NovoTAL System allows certified physicians to use a recurrent GBM patient's MRI data to optimize the distribution and intensity of NovoTTF Therapy....

2014-02-14 16:25:28

Featured Talk Emphasizes Importance of Antigen-Specific Dendritic Cell Cancer Vaccines to Generate Powerful T-Cell Response LOS ANGELES, Feb. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company's Founder and Chief Scientific Officer, John S. Yu, MD, delivered a presentation highlighting the therapeutic importance of utilizing antigen-specific dendritic cell (DC) cancer vaccines for inducing a potent T-cell...

2014-02-06 08:28:58

BETHESDA, Md., Feb. 6, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014. NW Bio's presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at the Waldorf-Astoria in New York...

2014-02-05 23:25:30

Moving the Needle in Brain Tumor Survivorship through Genomic Sequencing Seattle, WA (PRWEB) February 05, 2014 On January 22nd, 2014 the Chris Elliott Fund (CEF) and Foundation Medicine co-hosted a dinner in Seattle to share some of the latest developments in genomic profiling and the implications for brain tumor patients everywhere. The evening brought together a number of people from the Seattle Metro area: including patients, advocates, scientists, and physicians from Swedish Medical...

2014-02-04 11:57:02

Largest-ever study of 20-year survival among pediatric low-grade glioma patients highlights radiation's association with higher mortality The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults. However, children who received radiation as part of their treatment had significantly lower long-term...

2014-02-04 11:02:59

Presence of IDH1 mutation determines best treatment for malignant astrocytomas Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years. Now a new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Preliminary results of the study...

2014-01-28 23:31:05

In response to a January 20, 2014 article published by Futurity.org, Voices Against Brain Cancer discusses a new backdoor approach to treating glioblastoma and what it could mean for the brain cancer community. New York, NY (PRWEB) January 28, 2014 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to a January 20, 2014 article that discusses a new ‘backdoor’ approach to treat glioblastoma – the most common and fatal form of brain...

2014-01-27 08:27:57

Dr. Marnix Bosch To Describe DCVax-Direct Technology And Program BETHESDA, Md., Jan. 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will make a presentation concerning NW Bio's DCVax-Direct Phase I/II Trial for inoperable solid tumor cancers at Phacilitate's Washington...

2014-01-16 23:25:47

The Chris Elliott Fund, a 501(c)3 non-profit, held their grand opening on January 3rd. The center welcomes brain tumor patients, caregivers and family members seeking one-on-one help to their center and services. Redmond, WA (PRWEB) January 16, 2014 The Chris Elliott Fund (CEF) announced the grand opening of their Patient Support Services Center, a space devoted to serving brain cancer and brain tumor patients, their families and caregivers. The open house and ribbon cutting was on...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related